Combo HCV Promise Attracts Ascletis To Presidio Asset
This article was originally published in PharmAsia News
Executive Summary
China's Ascletis has struck another deal with a foreign licensor, acquiring rights in China to a hepatitis C virus (HCV) candidate being developed by Presidio that it intends to investigate in an all-oral, interferon-free combination.